The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency, and diagnostic performance while reducing system costs, which may increase accessibility and adoption in hospitals, clinics, veterinary, and dental sectors. The market report highlights how these trends create new opportunities beyond traditional radiology, supporting flexible diagnostic imaging and expanding the customer base. This evolution is expected to sustain demand and reshape the CT market landscape over the next five years.
The global computed tomography (CT) market innovation is the subject, with Pluang's health sector data providing context. As of Oct 23, 2026 20:21 WIB, out of 150 priced health-sector US stocks on Pluang, 28 rose and 119 fell. Notable movers include HRTX at USD 0.30 (+2.97%, 35% Sell / 65% Buy, typical hold time 37 days), NUWE at USD 0.50 (+2.50%, 0% Sell / 100% Buy, typical hold time 29 days), and BRKR at USD 56.00 (-2.29%, typical hold time 14 days).
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
